| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5273 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2751 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1652 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1325 | 2021 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 735 | 2021 |
| T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, ... Nature medicine 27 (2), 270-278, 2021 | 583 | 2021 |
| Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ... Nature medicine 27 (2), 279-288, 2021 | 330 | 2021 |
| A blood atlas of COVID-19 defines hallmarks of disease severity and specificity DJ Ahern, Z Ai, M Ainsworth, C Allan, A Allcock, B Angus, MA Ansari, ... Cell 185 (5), 916-938. e58, 2022 | 159 | 2022 |
| The clinical application of microRNAs in infectious disease RE Drury, D O’Connor, AJ Pollard Frontiers in immunology 8, 295828, 2017 | 155 | 2017 |
| Non-specific immunological effects of selected routine childhood immunisations: systematic review R Kandasamy, M Voysey, F McQuaid, K de Nie, R Ryan, O Orr, U Uhlig, ... bmj 355, 2016 | 98 | 2016 |
| Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection AJ Mentzer, D O’connor, S Bibi, I Chelysheva, EA Clutterbuck, T Demissie, ... Nature medicine 29 (1), 147-157, 2023 | 50 | 2023 |
| Searching for the human genetic factors standing in the way of universally effective vaccines AJ Mentzer, D O'Connor, AJ Pollard, AVS Hill Philosophical Transactions of the Royal Society B: Biological Sciences 370 …, 2015 | 46 | 2015 |
| Viral vector vaccines N McCann, D O’Connor, T Lambe, AJ Pollard Current Opinion in Immunology 77, 102210, 2022 | 44 | 2022 |
| Characterizing vaccine responses using host genomic and transcriptomic analysis D O'Connor, AJ Pollard Clinical infectious diseases 57 (6), 860-869, 2013 | 39 | 2013 |
| A naturally protective epitope of limited variability as an influenza vaccine target CP Thompson, J Lourenço, AA Walters, U Obolski, M Edmans, DS Palmer, ... Nature communications 9 (1), 3859, 2018 | 36 | 2018 |
| Common genetic variations associated with the persistence of immunity following childhood immunization D O’Connor, E Png, CC Khor, MD Snape, AVS Hill, F van der Klis, ... Cell reports 27 (11), 3241-3253. e4, 2019 | 29 | 2019 |
| Divergent trajectories of antiviral memory after SARS-CoV-2 infection A Tomic, DT Skelly, A Ogbe, D O’Connor, M Pace, E Adland, F Alexander, ... Nature Communications 13 (1), 1251, 2022 | 27 | 2022 |
| Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection R Tanner, I Satti, SA Harris, MK O'Shea, D Cizmeci, D O'Connor, ... Frontiers in immunology 10, 2983, 2020 | 27 | 2020 |
| The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age G Blanchard-Rohner, MD Snape, DF Kelly, D O’Connor, T John, ... Vaccine 31 (20), 2441-2448, 2013 | 26 | 2013 |
| The effect of chronic cytomegalovirus infection on pneumococcal vaccine responses D O'Connor, J Trück, R Lazarus, EA Clutterbuck, M Voysey, K Jeffery, ... The Journal of infectious diseases 209 (10), 1635-1641, 2014 | 25 | 2014 |
